Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282828 · ClinicalTrials.gov registry record · Phase 4
Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 397
- Enrollment target
NCT00282828: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00282828 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 397 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282828, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 397 participants
- Enrollment target
Study Summary
This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.
Interventions
- DRUG Placebo
- DRUG Sertraline
- DRUG Clonazepam
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282828
The ClinicalTrials.gov registry entry for NCT00282828 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00282828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282828 about?
NCT00282828 is a clinical study titled "Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder". This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.
What is the current status of trial NCT00282828?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 397 participants. The study started on 2006-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00282828?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG), Clonazepam (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00282828?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.